What is the impact on the treatment landscape from the early benefits seen in the EMPEROR trials? from Let's Talk! - Prof. Andrew Coats

Click on the timestamp to jump to the topic you are interested in.

• 00:24 Early benefits with empagliflozin observed in the EMPEROR-Reduced and EMPEROR-Preserved trials 00:59 In EMPEROR-Reduced, the significant reduction in primary endpoint is observed as early as 12 days 01:15 In EMPEROR-Preserved, the significant reduction in primary endpoint is observed as early as 18 days 01:36 Given the speed which we can protect patients, there is urgency to get patients under treatment